Home
About Us
Executive Leadership
Management Team
Board of Directors
Scientific Advisory Board
Pipeline
Technology
Conjugation Linker Technology
Manufacturing
Facilities
Contract Services
News & Publications
Press Releases
Inventprise In the News
Publications
Careers
Our People-First Philosophy
Join the Inventprise Team
Benefits
Contact
News & Publications
Inventprise Press Releases
Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate
•
January 2, 2024
New Inventprise Pneumococcal Vaccine Enters Phase 1/2 Clinical Evaluation
•
November 10, 2022
Inventprise Inaugurates Manufacturing Facility for High-Capacity Supply of Pneumococcal Conjugate Vaccines
•
May 10, 2022
Inventprise Receives $30M, Appoints New CEO and Expands Corporate Board
•
April 7, 2022
Inventprise Announces Investment of up to $90 Million to Advance its 25 Valent Pneumococcal Conjugate Vaccine Candidate into Proof-of-Concept Clinical Trials
•
November 10, 2021
Inventprise in the News
Inventprise CEO Attends 2nd Global Forum on Childhood Pneumonia
•
April 27, 2023
Every Breath Counts:
Pneumococcal Conjugate Vaccine Scorecard 2022
•
February 6, 2023
PATH: Inventprise’s Expanded-coverage Pneumococcal Vaccine Enters the Clinic
•
February 3, 2023
Precision Vaccinations: Pneumococcal Vaccines 2023
•
January 17, 2023
Gates Notes: A Promising New Vaccine to Protect Children from Their #1 Killer
•
September 6, 2022
Biospace: Gates Foundation Pours $90 Million into Promising New Pneumococcal Vaccine
•
November 11, 2021
GeekWire: Seattle-Area Startup Inventprise Gets Backing from Gates Foundation for Pneumonia Shot
•
November 10, 2021
Publications
Human Vaccines & Immunotherapies:
Multi-valent pneumococcal conjugate vaccine for global health: From problem to platform to production
•
August 22, 2022
Poster Presentation: Preclinical Results for a 25-Valent Penumococcal Conjugate Vaccine Using A Novel Linker Platform Technology – ISPPD-12 | June, 2022
•
June 22, 2022
